Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

NCT04163575 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
100
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Kecellitics Biotech Company Ltd

Collaborators